Eli Lilly’s Jaypirca (pirtobrutinib) has been shown to be superior to Johnson & Johnson (J&J) and AbbVie’s star Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) in chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL).
Conducted in treatment-naïve patients with CLL and SLL, the first-ever head-to-head trial found that Lilly’s oral therapeutic provokes a better overall response rate (ORR) in patients compared with Imbruvica.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Topline results from the Phase III BRUIN CLL-314 (NCT05254743) trial do not yet include progression-free survival (PFS) as the value is not yet mature. However, preliminary trends suggest that the non-covalent BTK inhibitor can also extend PFS for patients in both indications.
This builds on the positive results of the Phase III BRUIN CLL-321 trial (NCT04666038), which found that Jaypirca can reduce the risk of disease progression or death by 46% compared with Gilead’s Zydelig (idelalisib) plus Biogen and Genentech’s Rituxan (rituximab), and Teva Pharmaceuticals’ Treanda (bendamustine) plus Rituxan.
Jayprica poised to become SoC
BTK inhibitors are a highly popular option for the treatment of B-cell malignancies such as CLL and SLL, with many physicians using them in the first-line setting.
At the forefront of this drug class is Imbruvica, which raked in sales of $3.35bn in 2024 alone, according to AbbVie’s 2024 financial report.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHowever, a report from GlobalData, the parent company of Clinical Trials Arena, forecasts that Jaypirca is likely to become the BTK inhibitor market leader for CLL, with the therapy projected to make $5bn by 2032 — holding a 60% market share.
The positive topline results of the BRUIN CLL-314 trial could also result in Jaypirca being considered as standard of care (SoC) in CLL and SLL, further enhancing the therapy’s potential in this competitive market.
Lilly’s executive vice-president Jacob Van Naarden stated: “The positive topline results of this Phase III study will help us to build evidence supporting the potential role of Jaypirca in patients with CLL and SLL — hopefully enabling future regulatory approvals that allow physicians to use the medicine in various disease settings.”
